文献速递类风湿关节炎

GP2013与参照利妥昔单抗联合甲氨蝶呤治疗活动性类风湿关节炎生物等效性随机双盲试验

A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2017-06-21

该跨国随机双盲平行组研究纳入312例对TNFi应答不足或不耐受的活动性RA患者,比较GP2013与EU/US参照利妥昔单抗联合MTX的药代动力学和药效学等效性。结果显示所有比较的AUC几何均值比90%CI均在80%–125%等效限内,B细胞清除等效,疗效、安全性和免疫原性相似。

要点

  • GP2013与RTX-EU、RTX-US的AUC几何均值比90%CI均落在80%–125%等效限内。
  • 三方药效学等效性通过B细胞清除得到证实。
  • GP2013与参照利妥昔单抗的疗效、安全性和免疫原性相似。

核心结论

  • GP2013、RTX-EU和RTX-US三方药代动力学/药效学等效性得到证实。
  • GP2013与参照利妥昔单抗的疗效、安全性和免疫原性特征相似。

研究设计与样本

  • 跨国、随机、双盲、平行组研究,纳入312例对TNFi治疗应答不足或不耐受的活动性RA患者。
  • 患者随机接受GP2013或EU参照利妥昔单抗(RTX-EU)或US参照利妥昔单抗(RTX-US),联合甲氨蝶呤和叶酸。
  • 主要终点为血清浓度-时间曲线下面积(AUC0-inf),并评估至第24周的药代动力学、药效学、疗效、免疫原性和安全性。

主要发现

  • GP2013 vs RTX-EU的AUC几何均值比为1.106(90%CI 1.010–1.210)。
  • GP2013 vs RTX-US的AUC几何均值比为1.012(90%CI 0.925–1.108)。
  • RTX-EU vs RTX-US的AUC几何均值比为1.093(90%CI 0.989–1.208)。
  • 三方药效学等效性通过B细胞清除得到证实。
  • GP2013与RTX的疗效、安全性和免疫原性特征相似。

关键数值与推荐

  • 生物等效性限值为AUC几何均值比90%CI落在80%至125%之间。
  • 所有三方比较的90%CI均在该等效限内。

临床怎么用

  • GP2013可作为参照利妥昔单抗的生物类似药,联合甲氨蝶呤用于对TNFi应答不足或不耐受的活动性RA患者。
  • 临床使用时需关注其与参照利妥昔单抗相似的疗效、安全性和免疫原性特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this report is to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence as well as similar efficacy, safety and immunogenicity between GP2013, a biosimilar rituximab, and innovator rituximab (RTX) in patients with rheumatoid arthritis (RA) with inadequate response or intolerance to tumour necrosis factor inhibitor (TNFi) treatment. METHODS: In this multinational, randomised, double-blind, parallel-group study, 312 patients with active disease despite prior TNFi therapy were randomised to receive GP2013 or either the EU (RTX-EU) or the US (RTX-US) reference product, along with methotrexate (MTX) and folic acid. The primary endpoint was the area under the serum concentration-time curve from study drug infusion to infinity (AUC0-inf). Additional PK and PD parameters, along with efficacy, immunogenicity and safety outcomes were also assessed up to week 24. RESULTS: The 90% CI of the geometric mean ratio of the AUCs were within the bioequivalence limits of 80% to 125% for all three comparisons; GP2013 versus RTX-EU: 1.106 (90% CI 1.010 to 1.210); GP2013 versus RTX-US: 1.012 (90% CI 0.925 to 1.108); and RTX-EU versus RTX-US: 1.093 (90% CI 0.989 to 1.208). Three-way PD equivalence of B cell depletion was also demonstrated. Efficacy, safety and immunogenicity profiles were similar between GP2013 and RTX. CONCLUSIONS: Three-way PK/PD equivalence of GP2013, RTX-EU and RTX-US was demonstrated. Efficacy, safety and immunogenicity profiles were similar between GP2013 and RTX. TRIAL REGISTRATION NUMBER: NCT01274182; Results.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Smolen JS, Cohen SB, Tony HP, et al. A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2017. PMID: 28637670. doi:10.1136/annrheumdis-2017-211281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。